In a recent update that has the biotech community buzzing, Iovance Biotherapeutics unveiled promising data at the 2024 American Society of Clinical Oncology (ASCO) meeting. This news not only reinforces the potential of their newly marketed cell therapy, Amtagvi, but also sets…
